{"url_path":"/sec/allr/8-k/2026-06-22/item-9-01","section_key":"item-9-01","section_title":"Item 9.01 Financial Statements and Exhibits.**","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-22","source_url":"https://www.sec.gov/Archives/edgar/data/1860657/0001213900-26-070382-index.html","accession_number":"0001213900-26-070382","cik":"0001860657","ticker":"ALLR","issuer_name":"Allarity Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1860657/0001213900-26-070382-index.html","primary_entity_key":"0001860657","primary_entity_name":"Allarity Therapeutics, Inc."},"word_count":81,"has_tables":true,"body_markdown":"**Item 9.01 Financial Statements and Exhibits.**\n\n \n\n(d) Exhibits.\n\n \n\n**Exhibit\nNumber**\n \n**Description**\n\n \n \n\n99.1\n \n[Press Release, dated June 18, 2026.](ea029540901ex99-1.htm)\n\n104\n \nCover Page Interactive Data File (embedded within the Inline XBRL document).\n\n \n\n1\n\n \n\n \n\n**SIGNATURE**\n\n \n\nPursuant to the requirements\nof the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto\nduly authorized.\n\n \n\n \n**Allarity Therapeutics, Inc.**\n\n \n \n \n\nDate: June 22, 2026\nBy:\n/s/ Thomas H. Jensen\n\n \n \nThomas H. Jensen\n\n \n \nChief Executive Officer\n\n \n\n2"}